The Next Wave of Weight Loss and Diabetes Drugs: Multi-Target Peptide Agonists Beyond GLP-1

Narrative review of published preclinical and clinical evidence for novel dual and triple peptide agonists targeting GLP-1, GIP, glucagon, and GDF15 receptors. The review focuses on mechanisms of action, clinical efficacy data, and safety profiles.

The obesity and diabetes drug market is undergoing its most transformative period in history. Understanding the pipeline of multi-agonist peptides is essential for clinicians, researchers, and patients alike. Each additional receptor target adds efficacy but also complexity — knowing which combinations are most promising and what safety trade-offs exist will guide the next decade of metabolic pharmacotherapy.

The evolution from single-target GLP-1 agonists to multi-receptor peptides mirrors a broader trend in drug development toward polypharmacology — using one molecule to hit multiple targets. Tirzepatide (GLP-1/GIP) was the first approved dual agonist, and triple agonists like retatrutide are in Phase III trials. The addition of GDF15 as a target introduces a completely different appetite-regulation pathway, potentially addressing patients who don't respond well to incretin-based approaches alone.

As a review, no original data are presented. Many of the dual and triple agonists discussed are in early to mid-stage clinical development, and long-term efficacy and safety data are limited. The review explicitly excludes amylin analogs and other peptide approaches, so it does not cover the full landscape. The safety profiles of multi-agonist peptides are still being established, particularly for cardiovascular and gastrointestinal endpoints.